Innoviva Inc (INVA)

12.84
0.07 0.54
NASDAQ : Health Care
Prev Close 12.91
Open 12.97
Day Low/High 12.72 / 13.07
52 Wk Low/High 6.36 / 16.81
Volume 1.35M
Avg Volume 913.30K
Exchange NASDAQ
Shares Outstanding 109.20M
Market Cap 1.40B
EPS 0.50
P/E Ratio 24.26
Div & Yield N.A. (N.A)

Latest News

Innoviva Issues Press Statement

Innoviva Issues Press Statement

Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ: INVA) today issued the following statement.

Sarissa Capital Responds To Innoviva's Preemptive Launch Of Proxy Contest

Sarissa Capital Responds To Innoviva's Preemptive Launch Of Proxy Contest

Perplexed by Innoviva's decision to undertake a public contest rather than engage in constructive dialogue

Biotech Premarket Movers: Innoviva, Akebia, Geron

Biotech Premarket Movers: Innoviva, Akebia, Geron

Innoviva, Akebia Therapeutics and Geron were among the biotech stock movers in premarket trading on Tuesday.

Innoviva Files Preliminary Proxy Materials For 2017 Annual Meeting

Innoviva Files Preliminary Proxy Materials For 2017 Annual Meeting

Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ: INVA) today announced it is filing a preliminary proxy statement (the "Preliminary Proxy Statement") with the U.

Innoviva Reaches Analyst Target Price

Innoviva Reaches Analyst Target Price

In recent trading, shares of Innoviva Inc have crossed above the average analyst 12-month target price of $11.80, changing hands for $11.85/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Innoviva To Present At The Cowen & Co. 37th Annual Health Care Conference

Innoviva To Present At The Cowen & Co. 37th Annual Health Care Conference

Innoviva, Inc. (NASDAQ: INVA) announced today that Michael W.

Positive Results For Relvar® Ellipta® Lung Function Study In Patients With Well-Controlled Asthma

Positive Results For Relvar® Ellipta® Lung Function Study In Patients With Well-Controlled Asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive headline results from a non-inferiority lung function study, which demonstrated that patients with well-controlled...

Innoviva Reports Fourth Quarter And Full Year 2016 Financial Results

Innoviva Reports Fourth Quarter And Full Year 2016 Financial Results

Innoviva, Inc. (NASDAQ: INVA) today reported financial results for the fourth quarter and year ended December 31, 2016.

Innoviva To Report Fourth Quarter And Full Year 2016 Financial Results On February 9, 2017 At 5:00 P.m. EST

Innoviva To Report Fourth Quarter And Full Year 2016 Financial Results On February 9, 2017 At 5:00 P.m. EST

Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the fourth quarter and full year ended December 31, 2016 after market close on Thursday, February 9, 2017.

Interesting INVA Put And Call Options For September 15th

Interesting INVA Put And Call Options For September 15th

Investors in Innoviva Inc saw new options begin trading this week, for the September 15th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 227 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Innoviva Reaches Analyst Target Price

Innoviva Reaches Analyst Target Price

In recent trading, shares of Innoviva Inc have crossed above the average analyst 12-month target price of $11.60, changing hands for $11.64/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

GSK Starts Phase III Study Of Once-Daily Closed Triple Combination Therapy FF/UMEC/VI In Patients With Asthma

GSK Starts Phase III Study Of Once-Daily Closed Triple Combination Therapy FF/UMEC/VI In Patients With Asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the start of a phase III study investigating the effects of once-daily closed triple combination therapy fluticasone...

GSK Files Regulatory Submission In European Union For Once-Daily Closed Triple Combination Therapy FF/UMEC/VI For Patients With COPD

GSK Files Regulatory Submission In European Union For Once-Daily Closed Triple Combination Therapy FF/UMEC/VI For Patients With COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the European Medicines Agency for once-daily, closed triple combination therapy...

Relvar® Ellipta® 100/25 Mcg Gains Approval In Japan For Use In Patients With COPD

Relvar® Ellipta® 100/25 Mcg Gains Approval In Japan For Use In Patients With COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar ® Ellipta ® (fluticasone furoate /...

GSK Files Regulatory Submission In US For Once-Daily Closed Triple Combination Therapy FF/UMEC/VI For Patients With COPD

GSK Files Regulatory Submission In US For Once-Daily Closed Triple Combination Therapy FF/UMEC/VI For Patients With COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the US Food and Drug Administration for the once-daily, closed triple combination...

Innoviva To Present At The CreditSuisse And Stifel Healthcare Conferences In November

Innoviva To Present At The CreditSuisse And Stifel Healthcare Conferences In November

Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W.

Innoviva To Report Third Quarter 2016 Financial Results On October 27 At 5:00 P.m. EDT

Innoviva To Report Third Quarter 2016 Financial Results On October 27 At 5:00 P.m. EDT

Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the third quarter ended September 30, 2016 after market close on Thursday, October 27, 2016.

Innoviva Reaches Analyst Target Price

Innoviva Reaches Analyst Target Price

In recent trading, shares of Innoviva Inc have crossed above the average analyst 12-month target price of $11.25, changing hands for $11.29/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Innoviva To Present At Morgan Stanley Global Healthcare Conference And Rodman & Renshaw 19th Annual Global Investment Conference

Innoviva To Present At Morgan Stanley Global Healthcare Conference And Rodman & Renshaw 19th Annual Global Investment Conference

Innoviva, Inc. (NASDAQ:INVA) today announced that Michael W.

GSK Presents Positive Results From Phase III FULFIL Study Of Closed Triple Combination Therapy FF/UMEC/VI Versus Symbicort® Turbohaler® In COPD At ERS International Congress

GSK Presents Positive Results From Phase III FULFIL Study Of Closed Triple Combination Therapy FF/UMEC/VI Versus Symbicort® Turbohaler® In COPD At ERS International Congress

GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ:INVA) today announced the presentation of further data from the pivotal phase III FULFIL study with investigational closed triple combination therapy fluticasone...

Positive Results From The COPD Salford Lung Study Published In The NEJM And Presented At European Respiratory Congress

Positive Results From The COPD Salford Lung Study Published In The NEJM And Presented At European Respiratory Congress

GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ:INVA) today announced that the results from the pioneering Salford Lung Study (SLS) have been published in the New England Journal of Medicine (NEJM).

Innoviva To Present At Wells Fargo And Baird Healthcare Conferences In Early September

Innoviva To Present At Wells Fargo And Baird Healthcare Conferences In Early September

Innoviva, Inc. (NASDAQ:INVA) today announced that Michael W.

Overboarded Directors at Valeant, Yahoo! and Elsewhere Struggle With Activists, M&A

Overboarded Directors at Valeant, Yahoo! and Elsewhere Struggle With Activists, M&A

Board members who sit on four or more boards may find it impossible to manage their time when faced with an insurgent investor or merger situation -- or both.

Notable Wednesday Option Activity: INVA, TTNP, RPTP

Notable Wednesday Option Activity: INVA, TTNP, RPTP

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Innoviva Inc , where a total volume of 15,003 contracts has been traded thus far today, a contract volume which is representative of approximately 1.5 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 216.2% of INVA's average daily trading volume over the past month, of 693,865 shares.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BCC, CYS, DISH, ESRT, FCFS, FSI, GIMO, INVA, KSU, NATI, ORC, RMCF, TREE, WLDN, WMGI, WRE, ZION Downgrades: ACIW, ACOR, BSX, DLR, FI, HTH, IP, OVBC, SBBX Initiations: GNRT, MB, PUB Read on to get TheStreet Quant Ratings' detailed report:

Innoviva Reports Second Quarter 2016 Financial Results

Innoviva Reports Second Quarter 2016 Financial Results

Innoviva, Inc. (NASDAQ:INVA) today reported financial results for the second quarter ended June 30, 2016.

Innoviva (INVA) Is Today's Strong On High Volume Stock

Innoviva (INVA) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Innoviva (INVA) as a strong on high relative volume candidate